Drug Profile
Research programme: inflammation therapy - BioSeek/Dynavax
Latest Information Update: 16 Apr 2008
Price :
$50
*
At a glance
- Originator BioSeek; Dynavax Technologies
- Class Pyrimidines
- Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease; Inflammation; Rheumatoid arthritis
Most Recent Events
- 16 Apr 2008 Discontinued - Preclinical for Crohn's disease in USA (PO)
- 16 Apr 2008 Discontinued - Preclinical for Inflammation in USA (PO)
- 16 Apr 2008 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)